Vantrexa Sets High Standards for Retatrutide Research Materials in Metabolic Studies
Vantrexa, a professional laboratory supplier, is now offering research‑grade Retatrutide (LY3437943), a triple‑agonist targeting GLP‑1, GIP and glucagon receptors, for metabolic studies. The company employs advanced solid‑phase peptide synthesis and rigorous in‑house plus third‑party HPLC/LC‑MS testing, achieving purity levels above 99% and confirming a molecular weight of ~4,731 Da. All batches are delivered as lyophilized powder under inert nitrogen and accompanied by full analytical documentation through a public Research Hub. Vantrexa emphasizes a strict research‑only policy, ensuring compliance with global regulations.
Rhythm Pharmaceuticals Reports the EC Approval of Imcivree (Setmelanotide) for Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced that the European Commission has granted marketing authorization for Imcivree (setmelanotide) to treat acquired hypothalamic obesity in patients aged four years and older. The approval is based on the Phase III TRANSCEND trial, which enrolled 120 participants...
Novo Nordisk to Launch Ozempic for Type 2 Diabetes in US
Novo Nordisk will launch an oral version of Ozempic in the United States, following FDA approval that marks the first oral GLP‑1 drug cleared for both blood‑sugar control and cardiovascular risk reduction. The tablets, available in 1.5 mg, 4 mg and 9 mg...
Novel Wheat Hybrids Increase Resistance to Major Fungal Disease by up to 70%
Researchers have transferred a novel resistance locus from the wild weed Elymus repens into wheat, creating hybrids that slash Fusarium head blight (FHB) infection by up to 70%. The new locus, named Fhb.Er‑1StL, showed a 69% reduction in diseased spikelets...
Arvinas and Pfizer Report the US FDA Approval of Veppanu (Vepdegestrant) for ESR1-Mutated Breast Cancer
The U.S. FDA has approved Veppanu (vepdegestrant) for adults with ESR1‑mutated ER+/HER2‑ advanced or metastatic breast cancer who have received at least one line of endocrine therapy. The approval follows the Phase III VERITAC‑2 trial, which compared Veppanu to fulvestrant...
MAHA Vs. The FDA: Dredging up Old Anti-Regulation Revisionist History
A new essay in Science-Based Medicine denounces the “health‑freedom” narrative that seeks to dismantle the FDA. It traces the agency’s authority back to the 1962 Kefauver‑Harris amendment, which linked drug approval to rigorous safety and efficacy trials. The author dismantles...
65 % of Eligible Lung Cancer Patients Do Not Receive the Most Appropriate Targeted Therapies, Diaceutics Report Finds
Diaceutics’ 2026 Clinical Practice Gaps report shows that 65% of U.S. patients with advanced non‑small cell lung cancer still miss the most appropriate targeted therapy, a figure unchanged since 2019. While biomarker testing has improved, the biggest loss now occurs...
Artificial Retina Uses Biological Liquid Medium for Direct-to-Display ‘Vision’
Italian researchers led by Prof. Thomas M. Brown unveiled BIOPIX, a bio‑electronic hybrid retina emulator that embeds organic photodetectors in a liquid Ames medium. The proof‑of‑concept includes a 2 × 2 cone‑type array for colour and a 4 × 4 rod‑type array for grayscale,...
Novel Bioprinting Method Lays the Foundation for Personalised Regenerative Medicine
Researchers in Italy unveiled a solid‑electronics, liquid‑electrolyte sensor array that mimics retinal function, marking a proof‑of‑concept for bio‑integrated vision devices. A cell‑free hydrogel delivering extracellular vesicles showed efficacy in repairing intrauterine adhesions and restoring fertility in preclinical studies. An analysis...
Glowing Probe Detects Multiple Antibiotics with Just a Smartphone
Researchers in Italy unveiled a proof‑of‑concept sensor array that blends solid‑state electronics with a liquid electrolyte, effectively mimicking biological vision and allowing a smartphone to detect multiple antibiotics via fluorescence. In parallel, a heat‑resistant polyamide was engineered to emit pure...
FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate
May’s FDA docket is light, but the decisions on four high‑profile drugs could reshape market dynamics. Argenx is seeking to broaden Vyvgart’s label to seronegative myasthenia gravis patients, potentially adding 11,000 new users. AstraZeneca and Daiichi Sankyo aim to secure...
Viewpoint: How ‘Health Care Guru’ Joe Rogan Circumvented the FDA’s Skepticism on Psychedelics
Joe Rogan directly messaged President Donald Trump about the therapeutic potential of psychedelics, prompting the president to sign an executive order that fast‑tracks FDA review of these drugs. The order creates a priority‑voucher system that accelerates approvals for psychedelic manufacturers,...
Hidden Ingredient in GLP-1 Tablets Raises New Gut Health Questions
Oral semaglutide tablets rely on the absorption enhancer SNAC (salcaprozate sodium) to cross the stomach lining, but only 0.4%‑1% of the drug reaches the bloodstream. A 21‑day rat study published in the Journal of Controlled Release found that the majority...
FDA Clears GSK’s Gepotidacin, First New Oral UTI Antibiotic in 30 Years
The U.S. Food and Drug Administration has approved GSK’s gepotidacin (Blujepa) for uncomplicated urinary tract infections in females aged 12 and older, marking the first new oral antibiotic class for this indication in nearly 30 years. The decision follows pivotal...
Eli Lilly Inks $2.25 B Profluent Deal to Fast‑track AI‑driven Gene‑therapy Platform
Eli Lilly signed a research agreement worth up to $2.25 billion with AI protein‑design firm Profluent to develop next‑generation gene‑therapy candidates using AI‑engineered recombinases. The deal leverages cash from Lilly’s obesity drug franchise and adds to a string of multi‑billion‑dollar gene‑therapy...
Mitochondrial Dysfunction Drives Frailty; Biomarkers Needed for Precision Therapy
The mitochondrial side of frailty "Mitochondrial dysfunction lies at the intersection of musculoskeletal, metabolic, and immune changes underpinning frailty. While integrative biomarker panels have defined metabolic signatures, early diagnosis and personalized therapies remain unmet needs. Longitudinal studies are required to establish...
Study Links Oleic Acid to Faster Pancreatic Cancer, Fish Oil Cuts Risk 50%
Yale scientists reported that the type of dietary fat, not the total amount, drives pancreatic cancer development. Oleic acid—common in olive oil—accelerated tumor growth in mice, while omega‑3‑rich fish oil reduced disease burden by 50%, a finding that could reshape...
BioMarin Shows Long‑Term VOXZOGO Gains in Height, Arm Span and Bone Health
BioMarin Pharmaceutical announced new long‑term data for VOXZOGO® at the Pediatric Endocrine Society’s 2026 Annual Meeting, reporting up to 13.6 cm additional height after eight years, improved arm‑span Z‑scores and stable bone mineral density. The findings reinforce the drug’s position as...
Queensland Funds Research Into Cell-Based Therapies for Traumatic Brain Injury
The Queensland Government has pledged A$5.5 million (about US$3.6 million) over three years to the Cure TBI initiative, a research programme focused on cell‑based therapies for traumatic brain injury. Backed by the National Injury Insurance Scheme, Queensland (NIISQ), the effort will be...
UCB to Acquire Candid Therapeutics for $2 B, Adding T‑Cell Engager Platform to Immunology Portfolio
UCB announced a definitive agreement to acquire privately held Candid Therapeutics for $2 billion in cash, with up to $200 million in future milestones. The deal adds Candid’s lead bispecific antibody, cizutamig, and a pipeline of multi‑specific T‑cell engagers to UCB’s immunology...
AstraZeneca Posts 8% Revenue Rise in Q1 2026, Highlights Oncology Gains and Pipeline Progress
AstraZeneca announced an 8% jump in first‑quarter 2026 revenue, a 12% lift in operating profit and a core EPS of $2.58. Management credited new‑medicine demand, a 26% surge in alliance revenue, and robust oncology sales, while reaffirming full‑year guidance for...
FDA Expands Access to Daraxonrasib, Drug That Nearly Doubles Survival in Advanced Pancreatic Cancer
The U.S. Food and Drug Administration announced this week that it will broaden patient eligibility for Daraxonrasib, a targeted therapy that nearly doubled survival in a pivotal trial for advanced pancreatic cancer. The move follows growing clinical evidence and patient...
Low‑dose Endoxifen Cuts Breast Density, Fewer Side Effects
Low-dose endoxifen reduces breast density by up to 26%, matching the effect of tamoxifen but with fewer side effects, suggesting potential for improved preventive strategies in breast cancer. breastcancer
Hantaviruses Counteract Cell Interferon (IFN) Defense
Cells produce interferon when they are infected by viruses. It regulates antiviral responses. Cells produce interferon when infected with hantaviruses. Depending on the hantavirus, it may produce antagonists to counter the defense. And the convention is IFN, not INF. IYKYK
Low-Dose Drug Cuts Breast Density up to 26% with Fewer Side Effects
A Karolinska Institutet study found that low‑dose endoxifen, the active metabolite of tamoxifen, reduces mammographic breast density by up to 26%—comparable to the 18.5% reduction seen with standard 20 mg tamoxifen—while causing far fewer serious side effects. In a randomized, placebo‑controlled...
Reflecting on Craig Venter’s Pioneering Genome Era
I enjoyed this remembrance of Craig Venter and the early days of the genome project by @StevenSalzberg1. https://t.co/ggzbrvWlAk
Pharma Embraces AI, Yet Breakthrough Drugs Remain Elusive
JUST IN: The pharmaceutical industry is adopting AI, but new drug discovery through it remains elusive.
Krystal Biotech Inc (KRYS) Q1 2026 Earnings Call Transcript
Krystal Biotech reported Q4 2025 net VYJUVEK revenue of $107.1 million, a 34% year‑over‑year increase, pushing cumulative sales since launch past $730 million. The company maintained a 94% gross margin and posted $51.4 million of net income for the quarter, with cash and...
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics reported Q1 2026 product revenue of $15.8 million, a decline from the prior year, while GAAP net loss narrowed to $41 million ($0.30 per share). Operating expenses fell 12.1% on a non‑GAAP basis, driven by lower R&D spend. The company...
Travere Therapeutics Inc (TVTX) Q1 2026 Earnings Call Transcript
Travere Therapeutics reported record commercial performance for FILSPARI, posting $322 million in 2025 sales—a 144% year‑over‑year increase—and a Q4 record of 908 new patient start forms. The company secured a new FDA PDUFA target date of April 13, 2026 for the FSGS indication...
![Special Situation Setup: CVV Sum Of The Parts Mispricing + Biorem Q4 Management Briefing [Geowire Weekly No. 237]](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://geoinvesting.com/wp-content/uploads/2026/05/0503_thumbnail.png)
Special Situation Setup: CVV Sum Of The Parts Mispricing + Biorem Q4 Management Briefing [Geowire Weekly No. 237]
GeoInvesting’s weekly wrap‑up highlighted a special‑situations opportunity in CVV after a “blowout” quarter that may be mispriced under a sum‑of‑the‑parts analysis. The newsletter also featured Biorem Inc.’s Q4 2025 management briefing, where the CEO reported record backlog growth and stronger...
NHS Cancer Jab Could Save Patients Hours in Hospital
NHS England is introducing an injectable form of Keytruda, the blockbuster immunotherapy, that can be given in one to two minutes instead of the traditional hour‑long infusion. About 14,000 cancer patients in England start Keytruda each year, and most are...
Cell and Gene Therapy Funding Drops, M&A Persists
Investors should be aware of sub-sectors that fall in and out of favor amongst venture capital investors Cell and gene therapies have seen a marked decline in funding since last year. So have nucleic acid therapies, to a lesser extent However, these...
FDA OKs Bi‑weekly Teclistamab Dosing, Boosting Convenience in Relapsed Myeloma
The FDA has approved a supplemental Biologics License Application allowing teclistamab‑cqyv (Tecvayli) to be given at 1.5 mg/kg every two weeks for patients with relapsed/refractory multiple myeloma who have sustained a complete response for at least six months. The change follows...
UCLA Engineers RNA‑Based Programmable Artificial Organelles for Cellular Nanomachinery
A UCLA team has demonstrated a method to build programmable artificial organelles inside living cells using RNA as both material and blueprint. Published in Nature Nanotechnology, the work promises more efficient synthetic‑biology tools and could reshape nanotech‑enabled therapeutics.
Gene Signature Swiftly Distinguishes Ebola From Other Illnesses
A newly identified gene pattern enables rapid and accurate distinction of Ebola infection from other diseases, offering potential for improved diagnostic tests in outbreak scenarios. genomics
StockWatch: Patient Death, Rival’s Patent Challenge Sink Erasca Shares
Erasca (NASDAQ: ERAS) saw its shares plunge 53% after disclosing a patient death linked to its pan‑RAS drug ERAS‑0015 and a patent infringement claim from rival Revolution Medicine. The company reported unconfirmed overall response rates of 62%‑75% in KRAS G12X...
Molecular Diagnostics Boom: More Data, Consumer Market Ahead
Awesome, absolutely love this direction of molecular diagnostics/biomarker maximalism. We shouldn’t be afraid of more data. Especially excited to see it longitudinally for people. No reason this can’t be a big consumer market, paid out of pocket...
GLP Success Sparked Unstoppable Peptide Boom
The (hard for some to accept) reality is that the popularity of GLPs, which of course have lots of RCTs to support them, are actually what opened the doors for the immense interest in all the other peptides. People are...
CD44+ Monocytes Drive Inflammation in Preemie Lung Disease
Researchers have identified CD44⁺ monocytes as a key driver of hyperinflammatory responses in bronchopulmonary dysplasia (BPD) among very premature infants. The study shows these cells are markedly elevated in BPD patients and release amplified cytokine storms when exposed to hyperoxic...
Wearables Transform Clinical Trials with Continuous Real‑World Data
Delighted to share details on an exciting forum that we are hosting here at the Querrey Simpson Institute for Bioelectronics at @NorthwesternU — Advanced Wearable Sensors and the Future of Clinical Trials — on June 24, 2026, at the...
Glucagon Signaling Required for Caloric Restriction Benefits
Glucagon receptor signaling is indispensable for the healthspan effects of caloric restriction in aging male mice https://t.co/xZYiHWkw5s @GeroScienceAGE https://t.co/WcZgdHgsG2
Synthetic Biology Promised to Rewrite Life—With the Death of Its Pioneer, J. Craig Venter, How Close Are Scientists?
J. Craig Venter’s 2010 breakthrough—creating a cell controlled by a fully synthetic genome—proved that DNA could be written like software, launching modern synthetic biology. Since then researchers have engineered microbes to produce medicines such as artemisinin, explored bio‑fuel production, and built...
Nature Study Turns Into Immediate
I wrote about this 6 weeks ago at Ground Truths when the 2 @Nature papers by @HugoAerts and colleagues came out. Today it's a "Health Alert"! https://t.co/CgxBU7IAk1 https://t.co/24PijmLhzR
Extensive Edge‑Case Testing Ensures Plasmid Editor Robustness
Make a heap of edge case detection tests for my plasmid editor, even did emoji-as-input catches, lol. I take robustness and data integrity very seriously so I'm making sure all sorts of edge cases are handled gracefully. I even added...
DNA‑Based Gene Therapy Slashes LDL Cholesterol by 47% in Mice, Bypassing Statins
Researchers at the University of Barcelona and the University of Oregon reported that a DNA‑based molecule lowered LDL cholesterol by about 47% in mice after a single injection. The approach silences the PCSK9 gene without the muscle and liver side...
Longevity Genes Trade Growth for Extended Lifespan
if there were no aging, you would not have matured as a man in fact, the most powerful monogenic life-extending mutations in mice impair growth and maturation
Parexel Acquires Vitrana to Boost AI-Driven Patient Safety Platform
Parexel announced the acquisition of Vitrana, an AI‑enabled pharmacovigilance technology provider, to create a single‑partner model for safety services and software. Financial terms were not disclosed, but the deal expands Parexel’s AI capabilities and promises faster, more compliant adverse‑event processing...
Brain Complexity Enhances Premature Newborns’ Maturity Evaluation
Researchers have demonstrated that measuring brain signal complexity provides a reliable indicator of physiological maturity in premature newborns. Using high‑density EEG and advanced signal‑processing algorithms, the study linked specific complexity patterns to gestational age and future neurodevelopmental trajectories. The approach...
Axon Pathways Connect Small Gestational Age to Lung Restrictions
A 2026 Nature Communications study reveals that axon guidance pathways, traditionally linked to neural development, mediate the relationship between small for gestational age (SGA) birth and later spirometric restriction. Researchers analyzed genomic, transcriptomic and longitudinal lung‑function data from diverse cohorts...